Fixed combination calcipotriene plus betamethasone dipropionate aerosol foam is more efficacious than topical suspension, with similar tolerability, in patients with psoriasis vulgaris: The phase III PSO-ABLE study

doi:10.1016/j.jaad.2016.02.978

Fixed combination calcipotriene plus betamethasone dipropionate aerosol foam is more efficacious than topical suspension, with similar tolerability, in patients with psoriasis vulgaris: The phase III PSO-ABLE study

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2016.02.978 ◽

2016 ◽

Vol 74 (5) ◽

pp. AB251

Keyword(s):

Psoriasis Vulgaris ◽

Fixed Combination ◽

Betamethasone Dipropionate ◽

Phase Iii

Download Full-text

PSS9 Cost-per-Responder (CPR) of Fixed Combination Calcipotriol PLUS Betamethasone Dipropionate CAL/BD Cutaneous FOAM VS. CAL/BD GEL in Patients with Mild to Moderate Psoriasis vulgaris

Value in Health ◽

10.1016/j.jval.2020.08.1971 ◽

2020 ◽

Vol 23 ◽

pp. S734

Author(s):

N. Bithal ◽

F. Oluwa ◽

J.R. Treloggen

Keyword(s):

Psoriasis Vulgaris ◽

Fixed Combination ◽

Betamethasone Dipropionate ◽

Cost Per Responder

Download Full-text

Fixed combination calcipotriol plus betamethasone dipropionate aerosol foam in the treatment of psoriasis vulgaris: rationale for development and clinical profile

Expert Opinion on Pharmacotherapy ◽

10.1080/14656566.2016.1269749 ◽

2016 ◽

Vol 18 (1) ◽

pp. 115-121 ◽

Cited By ~ 8

Author(s):

Carle Paul ◽

Bo Bang ◽

Mark Lebwohl

Keyword(s):

Psoriasis Vulgaris ◽

Fixed Combination ◽

Clinical Profile ◽

Betamethasone Dipropionate

Download Full-text

An Applicator Delivery System for Fixed-Combination Calcipotriene Plus Betamethasone Dipropionate Topical Suspension (Gel): Innovating Psoriasis Vulgaris Treatment Through Patient Collaboration

Dermatology and Therapy ◽

10.1007/s13555-015-0087-0 ◽

2015 ◽

Vol 5 (4) ◽

pp. 235-246 ◽

Cited By ~ 2

Author(s):

Gritt Rasmussen ◽

Lene Lillevang Bech ◽

Torben Wager Nielsen

Keyword(s):

Delivery System ◽

Psoriasis Vulgaris ◽

Fixed Combination ◽

Betamethasone Dipropionate

Download Full-text

12797 Safety of long-term proactive management with fixed-dose combination calcipotriene 0.005% and betamethasone dipropionate 0.064% foam in patients with psoriasis vulgaris: Results of a phase III, multicenter, randomized, 52-week, vehicle-controlled trial

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2020.06.091 ◽

2020 ◽

Vol 83 (6) ◽

pp. AB1

Author(s):

Mark Lebwohl ◽

Jean Philippe Lacour ◽

Monika Liljedahl ◽

Charles Lynde ◽

Marie Mørch ◽

...

Keyword(s):

Psoriasis Vulgaris ◽

Controlled Trial ◽

Betamethasone Dipropionate ◽

Fixed Dose Combination ◽

Phase Iii ◽

Fixed Dose ◽

Proactive Management ◽

Dose Combination

Download Full-text

Fixed combination of tazarotene and betamethasone dipropionate for treatment of psoriasis vulgaris: The result of a phase 3, multicenter, randomized controlled trial

The Journal of Dermatology ◽

10.1111/1346-8138.15349 ◽

2020 ◽

Vol 47 (7) ◽

pp. 728-734

Author(s):

Hao Chen ◽

Jianfang Sun ◽

Haizhen Yang ◽

Qiuning Sun ◽

Jianzhong Zhang ◽

...

Keyword(s):

Randomized Controlled Trial ◽

Psoriasis Vulgaris ◽

Fixed Combination ◽

Controlled Trial ◽

Betamethasone Dipropionate ◽

Phase 3 ◽

Randomized Controlled ◽

Multicenter Randomized Controlled Trial

Download Full-text

18223 Long-term proactive management of psoriasis vulgaris with fixed-dose combination of 0.005% calcipotriene and 0.064% betamethasone dipropionate foam: Results of a phase III randomized controlled trial

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2020.06.919 ◽

2020 ◽

Vol 83 (6) ◽

pp. AB208

Author(s):

Mark Lebwohl ◽

Jean-Philippe Lacour ◽

Monika Liljedahl ◽

Charles Lynde ◽

Marie Holst Mørch ◽

...

Keyword(s):

Randomized Controlled Trial ◽

Psoriasis Vulgaris ◽

Controlled Trial ◽

Betamethasone Dipropionate ◽

Phase Iii ◽

Fixed Dose ◽

Randomized Controlled ◽

Proactive Management ◽

Dose Combination

Download Full-text

More rapid improvement in quality of life with fixed combination calcipotriene plus betamethasone dipropionate aerosol foam versus topical suspension (PSO-ABLE study in patients with psoriasis vulgaris)

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2016.02.1007 ◽

2016 ◽

Vol 74 (5) ◽

pp. AB260 ◽

Cited By ~ 4

Keyword(s):

Quality Of Life ◽

Psoriasis Vulgaris ◽

Fixed Combination ◽

Betamethasone Dipropionate ◽

Rapid Improvement

Download Full-text

Long-Term Proactive Management of Psoriasis Vulgaris with Fixed-Dose Combination of Calcipotriene 0.005% and Betamethasone Dipropionate 0.064% Foam: Results from a Phase III Randomized Controlled Trial

SKIN The Journal of Cutaneous Medicine ◽

10.25251/skin.4.supp.32 ◽

2020 ◽

Vol 4 (5) ◽

pp. s32

Author(s):

Mark Lebwohl ◽

Jean-Philippe Lacour ◽

Monika Liljedahl ◽

Charles Lynde ◽

Marie H Mørch ◽

...

Keyword(s):

Randomized Controlled Trial ◽

Psoriasis Vulgaris ◽

Controlled Trial ◽

Betamethasone Dipropionate ◽

Phase Iii ◽

Fixed Dose ◽

Randomized Controlled ◽

Proactive Management ◽

Dose Combination

Abstract not available.

Download Full-text

Cost-Per-Responder of Fixed Combination Calcipotriol + Betamethasone Dipropionate Aerosol Foam Vs Ointment In Patients With Psoriasis Vulgaris In The UK

Value in Health ◽

10.1016/j.jval.2017.08.2395 ◽

2017 ◽

Vol 20 (9) ◽

pp. A803-A804

Author(s):

A Walker ◽

F Oluwa ◽

J Riis Treloggen

Keyword(s):

Psoriasis Vulgaris ◽

Fixed Combination ◽

Betamethasone Dipropionate ◽

Cost Per Responder ◽

The Uk ◽

Calcipotriol Betamethasone

Download Full-text

Efficacy of an Innovative Aerosol Foam Formulation of Fixed Combination Calcipotriol plus Betamethasone Dipropionate in Patients with Psoriasis Vulgaris

Clinical Drug Investigation ◽

10.1007/s40261-015-0269-7 ◽

2015 ◽

Vol 35 (4) ◽

pp. 239-245 ◽

Cited By ~ 25

Author(s):

Catherine Queille-Roussel ◽

Martin Olesen ◽

John Villumsen ◽

Jean-Philippe Lacour

Keyword(s):

Psoriasis Vulgaris ◽

Fixed Combination ◽

Betamethasone Dipropionate ◽

Foam Formulation

Download Full-text